Enoxaparin may be safe for patients with cancer, brain metastases

Share this content:

the ONA take:

According to a new study published online in the journal Blood, researchers have found that patients with cancer and brain metastases who develop blood clots may safely receive enoxaparin, a type of low molecular weight heparin anticoagulant, without increased risk of intracranial hemorrhage.

For the study, researchers sought to assess the risk of intracranial hemorrhage, a dangerous form of bleeding in the head, associated with the administration of therapeutic doses of enoxaparin.

Researchers identified 239 patients with cancer and brain metastases. Of those, 104 received therapeutic enoxaparin and 189 were their matched controls that did not receive blood-thinning treatment.

Results showed that there were no differences in the cumulative incidence of intracranial hemorrhage at 1 year in the enoxaparin and control cohorts.

Researchers found that patients with melanoma or renal cell carcinoma had a fourfold higher risk of intracranial hemorrhage than those with lung cancer, but administration of enoxaparin did not affect that risk. The study also showed that overall survival was similar in both groups.

Brain mets
Patients with cancer and brain metastases who develop blood clots may safely receive enoxaparin.
Cancer patients with brain metastases who develop blood clots may safely receive blood thinners without increased risk of dangerous bleeding, according to a study, published online today in Blood, the Journal of the American Society of Hematology Cancer increases a patient's risk of developing blood clots.
READ FULL ARTICLE From Medical Express
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs